DexCom Inc. reported full-year (FY) 2025 revenue of USD 4.66 billion, representing a 16 percent increase. Gross profit for the period reached USD 2.80 billion, up 15 percent. Operating income was USD 911.8 million, a 52 percent rise, and net income totaled USD 836.3 million, an increase of 45 percent. Operating cash flow for the year was USD 1.44 billion, up 46 percent. The company ended FY 2025 with cash, cash equivalents, and short-term marketable securities of USD 2.00 billion. Key business highlights for the period included the launch of DexCom's G7 15 Day system in late 2025, following the introduction of the G7 in 2023. In August 2024, DexCom also launched Stelo, its over-the-counter glucose biosensor for adults with prediabetes and Type 2 diabetes not using insulin, marking the first such biosensor available in the U.S. The company added approximately 600,000 to 700,000 net customers, excluding Stelo customers, to its worldwide customer base during 2025. The revenue growth was primarily driven by increased sales volume of disposable sensors, reflecting continued global customer base expansion, partially offset by pricing headwinds from greater rebate eligibility and channel mix.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DexCom Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001093557-26-000027), on February 12, 2026, and is solely responsible for the information contained therein.